{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:45:35Z","timestamp":1791215135266,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024838","name":"Samsung Medical Center, Sungkyunkwan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gim.2025.101460","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T12:14:16Z","timestamp":1747829656000},"page":"101460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort"],"prefix":"10.1016","volume":"27","author":[{"given":"Young Bae","family":"Sohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsup","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-2706","authenticated-orcid":false,"given":"Dong-Kyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gim.2025.101460_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.gim.2025.101460_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.accb.2019.09.001","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment","volume":"77","author":"Mohamed","year":"2020","journal-title":"Adv Carbohydr Chem Biochem"},{"issue":"3","key":"10.1016\/j.gim.2025.101460_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"1-2","key":"10.1016\/j.gim.2025.101460_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in the Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum Genet"},{"issue":"6","key":"10.1016\/j.gim.2025.101460_bib5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","article-title":"Cumulative incidence rates of the mucopolysaccharidoses in Germany","volume":"28","author":"Baehner","year":"2005","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.gim.2025.101460_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF00569230","article-title":"Incidence of Hunter\u2019s syndrome","volume":"60","author":"Young","year":"1982","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/j.gim.2025.101460_bib7","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.gim.2025.101460_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gim.2025.101460_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1005335624386","article-title":"Molecular analysis in 23 Hunter disease families","volume":"20","author":"Lissens","year":"1997","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.gim.2025.101460_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/hmg\/6.3.479","article-title":"Molecular and phenotypic variation in patients with severe Hunter syndrome","volume":"6","author":"Timms","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.gim.2025.101460_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/humu.9128","article-title":"Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations","volume":"21","author":"Kim","year":"2003","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.gim.2025.101460_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1399-0004.2011.01641.x","article-title":"Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type II","volume":"81","author":"Sohn","year":"2012","journal-title":"Clin Genet"},{"issue":"8","key":"10.1016\/j.gim.2025.101460_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2025.101460_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gim.2025.101460_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2025.101460_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-015-0356-0","article-title":"Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II","volume":"10","author":"Cho","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gim.2025.101460_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gim.2025.101460_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.gim.2025.101460_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/jhg.2016.133","article-title":"Comparative study of idursulfase beta and idursulfase in vitro and in vivo","volume":"62","author":"Kim","year":"2017","journal-title":"J Hum Genet"},{"issue":"4","key":"10.1016\/j.gim.2025.101460_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10719-014-9523-0","article-title":"A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of Hunter syndrome","volume":"31","author":"Chung","year":"2014","journal-title":"Glycoconj J"},{"issue":"5","key":"10.1016\/j.gim.2025.101460_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","article-title":"The use of external controls in FDA regulatory decision making","volume":"55","author":"Jahanshahi","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"10.1016\/j.gim.2025.101460_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chest.2019.10.014","article-title":"Six-minute walk test: clinical role, technique, coding, and reimbursement","volume":"157","author":"Agarwala","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.gim.2025.101460_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.gim.2025.101460_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.17816\/2686-8997-2020-1-4-242-247","article-title":"Clinical experience of replacing enzyme replacement therapy in a patient with mucopolysaccharidosis type II","volume":"1","author":"Kuzenkova","year":"2020","journal-title":"Badalyan Neuro J"},{"key":"10.1016\/j.gim.2025.101460_bib25","article-title":"Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: a case series","volume":"36","author":"Chan","year":"2023","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.gim.2025.101460_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gim.2025.101460_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol Genet Metab"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025001078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025001078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:24:14Z","timestamp":1786663454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360025001078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1098360025001078"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2025.101460","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2025.101460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"101460"}}